Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 4INDUSTRY 2NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Breast Neoplasms 61HER2-positive Breast Cancer 10Neoplasm Metastasis 5Ovarian Neoplasms 4Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Stomach Neoplasms 3Solid Tumor 2Prostatic Neoplasms 2Endometrial Neoplasms 2Brain Neoplasms 2Biliary Tract Neoplasms 2Urinary Bladder Neoplasms 1Solid Tumors 1Solid Cancers 1Solid Cancer 1Resectable HER2-positive Breast Cancer 1Recurrence 1Patient Preference 1Neoplasms, Unknown Primary 1Lung Neoplasms 1Liver Neoplasms 1Inflammatory Breast Neoplasms 1HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients 1HER2-positive Early Breast Cancer 1HER2-Positive Early Breast Cancer 1Gastrointestinal Neoplasms 1Fallopian Tube Neoplasms 1Early-stage or Locally Advanced HER2-positive Breast Cancer 1Early or Locally Advanced HER2-positive Breast Cancer 1

Interventions

Prednisone 102enzalutamide 74Docetaxel 72Abiraterone Acetate 67Leuprolide 47acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 45abiraterone 37apalutamide 28Prednisolone 27bicalutamide 26Zoledronic Acid 24pembrolizumab 22Goserelin 22radium Ra 223 dichloride 21darolutamide 21Triptorelin Pamoate 17cabazitaxel 15Androgen Antagonists 15sipuleucel-T 13luprolide acetate gel depot 12Injections 12Dexamethasone 12olaparib 11gallium 68 PSMA-11 10Mitoxantrone 10Pluvicto 9Ipilimumab 9Dutasteride 9Cyclophosphamide 9relugolix 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Prostatic Neoplasms × pertuzumab × Clear all
NCT02480010 2015-09-18

A Study of Pertuzumab in Participants With Prostate Cancer

Hoffmann-La Roche

Phase 2 Terminated
68 enrolled 18 charts
Genitourinary

Prostatic Neoplasms

NCT00058539 2015-06-23

Safety and Efficacy Study of Pertuzumab to Treat Castration-Resistant Prostate Cancer

Genentech, Inc.

Phase 2 Completed
42 enrolled 10 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡